単純ヘルペスウィルス(PX)ワクチンの世界市場

◆英語タイトル:MarketVIEW: Herpes Simplex Virus (PX) vaccines
◆商品コード:VACZ712005
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年3月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD6,250 ⇒換算¥693,750見積依頼/購入/質問フォーム
PDF+ExcelUSD8,940 ⇒換算¥992,340見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.
Vaccine manufacturers have pursued the development of prophylactic (PX) HSV vaccines albeit with little success to date (note: GSK’s Simplirix). Mathematical modelling has indicated that mass vaccination with a HSV vaccine that can prevent the establishment of viral latency and shedding could substantial reduce disease burden and economic cost. Sanofi Pasteur is clinically testing a replication-defective mutant virus, HSV529.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a PX HSV vaccines across major Western markets + BRIC-M to 2040. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing, and penetration estimates. LO/BASE/HI target product profile (TPP) pricing scenarios are included which examine the uptake of vaccines across successive population groups. A detailed review is also included on latest trends in disease epidemiology/dynamics/competitive environment.

【レポートの目次】

Contents – Summary presentation (.pdf)
Author’s note
Executive summary
HSV prophylactic vaccines: Key commercial model outputs
HSV PX vaccine: forecast revenues ($m) to 2040 (global)
HSV PX vaccine: predicted volume (000s doses) to 2040 (global)
HSV PX vaccine: pricing simulations (base scenario) to 2040
HSV PX vaccine: forecast revenues ($m) by group (high)
HSV PX vaccine: forecast revenues ($m) by geography (high)
HSV PX vaccine: forecast revenues ($m) by country to 2040 (high)
HSV PX vaccine: volume by segment to 2040 (high)
Herpes simplex virus: disease background
HSV – the pathogen
Life cycle and pathogenesis of HSV
HSV-1 and HSV-2 life cycles
Diagnosis of HSV infection
Clinical manifestations of HSV-1 and HSV-2
Association of HSV-2 and human immunodeficiency virus
Rare, deadly outcomes of HSV infection: neonatal herpes
Rare, deadly outcomes of HSV infection: HSV encephalitis
Serious morbidity associated with HSV: herpes simplex keratitis
Clinical reactivation of HSV-1 and HSV-2
Disease burden of HSV
Economic burden of HSV
Summary: HSV-1/HSV-2
Herpes simplex virus: review of disease epidemiology
Epidemiology of HSV
Prevalence of HSV-2 infection in 2012 by WHO region
HSV-1/HSV-2 diagnosis and surveillance
Epidemiology: UK
Epidemiology: US
2 Model contents are available upon request

Epidemiology: other markets
HSV-1 and HSV-2 seroprevalence studies
HSV-1 as an emerging cause of genital herpes
Herpes simplex virus: Current management strategies
Current management of genital herpes
2016 WHO recommendations for the treatment of genital HSV
Herpes simplex virus prophylactic vaccines: rationale for development, case studies
Evidence that an HSV vaccine is feasible
Two approaches to HSV vaccination
Unmet need for a prophylactic HSV vaccine
HSV PX vaccines past failures: Simplirix (GSK) case study
Herpevac trial - main results
Why was Simplirix unsuccessful?
Potential public health impact of HSV-2 vaccines
Herpes simplex virus vaccines: overview of current research and development
HSV PX vaccines: overview
HSV PX vaccines: pipeline table
HSV prophylactic vaccines: Target product profile (TPP)
HSV prophylactic vaccines: Commercial model assumptions
Overall modelling approach and rationale
Markets modelled in this analysis
Commercial model assumptions (detailed)
HPV prophylactic vaccine schedules and HSV coverage
HSV-1 and HSV-2 seroprevalence studies: model inputs
Summary of the five groups making up the three scenarios
Model caveats and limitations
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 80 MS slides, fully referenced/sourced. Available in .pdf form

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 単純ヘルペスウィルス(PX)ワクチンの世界市場(MarketVIEW: Herpes Simplex Virus (PX) vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆